MS200647-0020/BREAST020

A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer

Ouvert à Saint-Cloud depuis le : 19/03/2021
Public cible : Adult
Phase : Phase II

Description de l'essai

The main purpose of this study is to evaluate bintrafusp alfa monotherapy in participants with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a centralized reverse transcriptase-polymerase chain reaction (RT-PCR) test.

Url of the trial

Investigateur principal

FRANCOIS-CLEMENT BIDARD

Professeur - Médecin

Contacter